

Press release from Emotra AB (publ)

Göteborg, April 22, 2021

EMOTRA AB: Ingela Hallberg has been nominated to the board of directors of Emotra AB

At this year's regular shareholder meeting, Emotra AB ("Emotra" or "the Company") will propose the re-election of the directors Claes Holmberg, Jan Pilebjer, Anna Sjörs and Lars-Håkan Thorell and the nomination of Ingela Hallberg as a new director.

Ingela Hallberg

Born 1955

Ingela Hallberg is a medical doctor with clinical experience from Sahlgrenska University Hospital in Göteborg. Ingela has more than 20 years' experience in management positions in the pharmaceutical industry at a number of large companies such as Bayer, Lundbeck, Merck KgA, Otsuka and the CRO Quntiles (now IQVIA), in both research and strategic positions. For a little more than a year, Ingela has been self-employed helping start-ups and smaller companies in the life science sector with medical, strategic and clinical development questions. Ingela is also a member of the boards of the life science companies Cellink AB since 2017 and MedVasc AB since 2019.

Ingela does not own any shares in Emotra.

According to the Swedish Corporate Governance Code ("the Code"), Ingela is considered independent, both in relation to the Company and to its larger shareholders.

For further information about Emotra, please contact:

Daniel Poté, CEO, telephone: +46 732 34 41 93, E-mail: daniel@emotra.se

Emotra AB (publ) is a medical technology company that carries out research, development, clinical studies and marketing in the area of mental health. The Company's method, EDOR[®], is a proprietary and objective psychophysiological test for detecting if patients suffering from depression are hyporeactive.

Emotra AB, AstraZeneca BioVentureHub, Pepparedsleden 1
SE-431 83 Mölndal, Sweden. Tel: +46 73 234 41 93, www.emotra.se